The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Risperidone augmentation in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study
Open accessAbstract
This double-blind, placebo-controlled trial was performed to determine the efficacy and tolerability of 8 wk of risperidone augmentation of serotonin reuptake inhibitor (SRI) treatment in adult subjects with treatment-resistant obsessive-compulsive disorder (OCD) (failure of at least two SRI trials). Sixteen adult treatment-resistant OCD patients were randomly assigned to augmentation with 8 wk of either risperidone (n=10) (0.5-3.0 mg/d) or placebo (n=6) following at least 12 wk of SRI treatment. Four patients on risperidone (40%) and none (0%) on placebo were responders with both a Clinical Global Impression - Improvement (CGI-I) score of 1 or 2 and a Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) decrease >/=25%. Risperidone was generally well tolerated: there were 3 dropouts, 1 on risperidone and 2 on placebo. Better Y-BOCS insight score at baseline significantly correlated with a greater CGI-I score at endpoint on risperidone augmentation. Risperidone may be an effective and well-tolerated augmentation strategy in treatment-resistant OCD subjects, but larger sample size studies are required to demonstrate this.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, second-generation antipsychotic agents have shown benefit, either alone or as adjunctive therapy. Specifically, high-dose olanzapine [522], quetiapine [523], and risperidone [524] have all shown at least minimal clinical benefit relative to placebo treatment [525].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [524]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
The Yale-Brown Obsessive-Compulsive Scale: measures of internal consistency.
Kim, S.-W., Dysken, M., Pheley, A., & Hoover, K. M. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90039-6 · Cited by 2,333
Ostwald, P. F. (1960) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1960.14.4.817 · Cited by 1,422
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
Haloperidol Addition in Fluvoxamine-Refractory Obsessive-Compulsive Disorder
McDougle, C. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040046006 · Cited by 566
Clinical Predictors of Drug Response in Obsessive-Compulsive Disorder
Erzegovesi, S., Cavallini, M. C., Cavedini, P., Diaferia, G., Locatelli, M., & Bellodi, L. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00006 · Cited by 224
Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
Saxena, S., Wang, D., Bystritsky, A., & Baxter, L. R. (1996) · PubMed · Cited by 154
Insight and treatment outcome in obsessive-compulsive disorder
Eisen, J. L., Rasmussen, S. A., Phillips, K. A., Price, L. H., Davidson, J. R. T., Lydiard, R. B., Ninan, P. T., & Pigott, T. A. (2001) · Comprehensive Psychiatry · doi:10.1053/comp.2001.27898 · Cited by 152
Insight and Resistance in Patients with Obsessive-Compulsive Disorder
Catapano, F., Sperandeo, R., Perris, F., Lanzaro, M., & Maj, M. (2001) · Psychopathology · doi:10.1159/000049282 · Cited by 124
Low-dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania
Stein, D. J. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90462-9 · Cited by 123
Olanzapine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder
Koran, L. M., Ringold, A. L., & Elliott, M. A. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0709 · Cited by 111
Risperidone augmentation in refractory obsessive—compulsive disorder: an open-label study
Pfanner, C., Marazziti, D., Dell’Osso, L., Presta, S., Gemignani, A., Milanfranchi, A., & Cassano, G. B. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015050-00007 · Cited by 83
Ramasubbu, R., Ravindran, A. V., & Lapierre, Y. D. (2000) · Pharmacopsychiatry · doi:10.1055/s-2000-8360 · Cited by 74
Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder
Mohr, N., Vythilingum, B., Emsley, R. A., & Stein, D. J. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200201000-00006 · Cited by 69
Update on pharmacologic management of OCD: agents and augmentation.
McDougle, C. J. (1997) · PubMed · Cited by 65
Clinical predictors of drug response in obsessive-compulsive disorder
Denys, D. A. J. P., van Megen, H. J. G. M., & Westenberg, H. G. M. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)80566-1 · Cited by 13
Hantouche, E. G., Bouhassira, M., & Lancrenon, S. (2001) · PubMed · Cited by 7
Risperidone augmentation in refractory obsessive compulsive disorder: An open-label study
Pfanner, C., Marazziti, D., Dell’Osso, L., Presta, S., Gemignani, A., Milanfranchi, A., & Cassano, G. B. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)80450-2 · Cited by 6
Cited by
Sorted by citations
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“As adjunctive therapy for treatment-resistant OCD, risperidone was more effective than placebo (Level 1) [756-759] and as effective as olanzapine [760] and aripiprazole overall [755].”
BackgroundPractice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Self-citationBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H., & WFSBP Task Force on Treatment Guide (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 887
Self-citationBloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001823 · Cited by 635
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
Metadata
- Authors
- Hollander, E., Rossi, N. B., Sood, E., & Pallanti, S.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- University of Pisa (IT)
- University of Florence (IT)
- Corresponding author
- Hollander, Eric
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-12
- Volume
- 6
- Issue
- 4
- Pages
- 397-401
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W1966161934
- Cited by
- 197
- References
- 19
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 5 · 2023: 3 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 7 · 2018: 8 · 2017: 7 · 2016: 5 · 2015: 16 · 2014: 10 · 2013: 7 · 2012: 10
- FWCI
- 17.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Funders
- Janssen Pharmaceuticals
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- risperidone, treatment-resistant OCD, augmentation therapy, serotonin reuptake inhibitors, antipsychotic augmentation, drug tolerability, treatment response, insight, Yale-Brown Obsessive Compulsive Scale, Clinical Global Impression Scale
- MeSH terms
- Adult, Ambulatory Care, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Drug Resistance, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Personality Inventory, Antipsychotic Agents, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
